Application of SBDD to the discovery of new antibacterial drugs

Methods in Molecular Biology

Volumn 841, Issue , 2012, Pages 291-319

  Finn, John ^a  

^a Trius Therapeutics   (United States)

Author keywords

Antibiotics; Drug Properties; Ligand Efficiency; Structure Based Drug Design

Indexed keywords

ANTIINFECTIVE AGENT;

ARTICLE; BACTERIUM; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECT; HIGH THROUGHPUT SCREENING; MICROBIOLOGICAL EXAMINATION; SYNTHESIS;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE;

EID: 84856483002     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-520-6_13     Document Type: Article

References (56)

1. Arias, C. A. and Murray B. (2009) Antibiotic- Resistant Bugs in the 21st Century: A Clinical Super-Challenge. N. Engl. J. Med. 360 , 439-443
2. Boucher, H.W., Talbot, G. H., Bradley, J.S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B. and Bartlett, J. (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Diseases 48 , 1-12.
3. Giske, C., Monnet, D., Cars, O. and Carmeli, Y. (2008) Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli. Antimicrob. Agents Chemother. 52 , 813-821. (Pubitemid 351358357)
4. Overbye, K. and Barrett, J. (2005) Antibiotics: where did we go wrong? Drug Discovery Today 10 , 45-52. (Pubitemid 40164818)
5. Bush, K. (2004) Antibacterial drug discovery in the 21st century. Clin. Microbiol. Infect. Suppl. 4 , 10-17.
6. Payne, D., Gwynn, M., Holmes, D. and Pompliano, D. (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Disc. 6 , 29-40. (Pubitemid 46020284)
7. Stein, J. (2005) Innovative antibacterial drugs: nothing ventured, nothing gained. Expert Opin. Investig. Drugs 14 , 107.
8. Kompis, I., Islam, K. and Then, R. (2005) DNA and RNA Synthesis: Antifolates Chem. Rev . 105 , 593-620. (Pubitemid 40351635)
9. Bushby, S. R. (1973) Trimethoprimsulfamethoxazole. In vitro microbiological aspects. J. Infect. Diseases 128 (Suppl.) S442-S462.
10. Canton, R., Loza, E., Morosini, M. and Baquero, F. (2002) Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance program during 1999-2000. J. Antimicrob. Chemother. 50(Suppl. S1) , 9-24.
11. Dale, G., Broger, C., D'Arcy, A., Hartman, P., DeHoogt, R., Jolidon, S., Kompis, I., Labhardt, A., Langen, H., Locher, H., Page, M., Stueber, D., Then, R., Wipf, B. and Oefner, C. (1997) A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance. J. Mol. Bio . 266 , 23-30. (Pubitemid 27170515)
12. Vickers, A., Potter, N., Fishwick, C., Chopra, I. and O'Neill, A. (2009) Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques. J. Antimicrob. Chemother. 63 , 1112-1117.
13. Kujundzic, N., Kovacevic, K., Jakovina M. and Gluncic, B. (1988) Synthesis and antibacterial effect of derivatives of 5-(3,4,5-trimethoxybenzyl) pyrimidine, -tetrahydropyrimidine, -hexahydropyrimidine and -hydantoin. Croatica Chemica Acta 61 , 121-35.
14. Summerfield, R., Daigle, D., Mayer, S., Mallik, D., Hughes, D., Jackson, S., Sulek, M., Organ, M., Brown, E. and Junop, M. (2006) Pharmacophoric Features of Biguanide Derivatives: An Electronic and Structural Analysis. J. Med. Chem. 49, 6977-6986
15. Kohlhoff, S. and Sharma, R. (2007) Iclaprim. Expert Opin. Invest. Drugs 16 , 1441-1448. (Pubitemid 47491413)
16. Peppard, W. and Schuenke, C. (2008) Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr. Opin. Invest. Drugs 9 , 210-225. (Pubitemid 351206380)
17. Schneider, P., Hawser, S. and Islam, K. (2003) Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg. Med. Chem. Lett. 13 , 4217-4221. (Pubitemid 37410316)
18. Oefner, C., Bandera, M., Haldimann, A., Laue, H., Schulz, H., Mukhija, S., Parisi, S., Weiss, L., Lociuro, S. and Dale, G. (2009) Increased hydrophobic interactions of Iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J. Antimicrob. Chemother. 63 , 687-698.
19. Hawser, S., Haldimann, A., Parisi, S., Gillessen, D. and Islam, K. (2002) "AR-100, A Novel Diaminopyrimidine Compound: resistance studies in Trimethoprim-Sensitive and -Resistant Staphylococcus aureus " 42 nd ICAAC Meeting ; San Diego, CA (poster F-2028).
20. Brandt, R., Neuenhofer, D., Thomsen, T., Hadvary, P. andIslam, K.(2007)"Pharmacokinetics and bioavailability of Iclaprim oral and intravenous formulations in humans" 47 th ICAAC Meeting ; Chicago, IL (poster A-806).
21. Krievins, D., Brandt, R., Hawser, S., Hadvary, P. and Islam, K. (2009) Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. Antimicrob. Agents Chemother. 53 , 2834-2840.
22. Wyss, P., Guerry, P., Hartman, P., Hubschwerlen, C., Jolidon, S., Locher, H., Specklin, J. and Stalder, H. (1999) "Anti-MRSA Dihydrofolate Reductase Inhibitors: Synthesis and SAR" 39 th ICAAC Meeting ; San Francisco, CA (poster F-1800).
23. Locher, H., Wyss, P., Then, R. and Hartman, P. (1999) "Anti-MRSA Dihydrofolate Reductase Inhibitors: Biological Characterization" 39 th ICAAC Meeting ; San Francisco, CA (poster F-1801).
24. Mukhija, S., Bandera, M., Parisi, S., Rigo, S., Lieb, S., Lociuro, S., Gillessen, D. and Islam, K. (2005) "AR-709 - An Investigational diaminopyrimidine: Inhibition, Binding and Mode of Action" 47 th ICAAC Meeting ; Chicago, IL (poster F1-1955).
25. Jansen, W., Verel, A., Verhoef, J. and Milatovic, D. (2008) In vitro activity of AR - 709 against Streptococcus pneumoniae . Antimicrobial Agents and Chemotherapy 52 , 1182-1183. (Pubitemid 351358413)
26. Hawser, S., Bihr, M., Weiss, L., Islam, K. and Lociuro, S. (2007) "AR-709, A Novel Diaminopyrimidine Compound: Resistance Studies in Trimethoprim-sensitive and -resistant Bacteria" 47 th ICAAC Meeting ; Chicago, IL (poster F1-1960).
27. Lappin, G., Warrington, S., Sanghera, D., Dowen, S., Lister, N., Islam, K. and Lociuro, S. (2007) "Plasma Pharmacokinetics Of AR-709 Administered to Male Healthy Volunteers as Microdoses by the Intravenous and Oral Route" 47 th ICAAC Meeting ; Chicago, IL (poster F1-939).
28. Wyss, P., Gerber, P., Hartman, P., Hubschwerlen, C., Locher, H., Marty, H. and Stahl, M. (2003) Novel Dihydrofolate Reductase Inhibitors. Structure-Based versus Diversity-Based Library Design and High-Throughput Synthesis and Screening. J. Med. Chem. 46 , 2304-2312. (Pubitemid 36637915)
29. Sanders, W., Nienaber, V., Lerner, C., McCall, J., Merrick, S., Swanson, S., Harlan, J., Stoll, V., Stamper, G., Betz, S., Condroski, K., Meadows, R., Severin, J., Walter, K., Magdalinos, P., Jakob, C., Wagner, R. and Beutel, B. (2004) Discovery of Potent Inhibitors of Dihydroneopterin Aldolase Using CrystaLEAD High-Throughput X-ray Crystallographic Screening and Structure-Directed Lead Optimization. J. Med. Chem. 47 , 1709-1718. (Pubitemid 38380914)
30. Lever, O. W., Bell, L. N., Hyman, C., McGuire, H. M. and Ferone, R. (1986) Inhibitors of dihydropteroate synthase: substituent effects in the side-chain aromatic ring of 6-[[3-(aryloxy) propyl]amino]-5-nitrosoisocytosines and synthesis and inhibitory potency of bridged 5-nitrosoisocytosine-p- aminobenzoic acid analogs . J. Med. Chem. 29 , 665-670. (Pubitemid 16034673)
31. Lever, O. W., Bell, L. N., McGuire, H. M. and Ferone, R. (1985) Monocyclic pteridine analogs. Inhibition of Escherichia coli dihydropteroate synthase by 6-amino-5-nitrosoisocytosines. J. Med. Chem . 28 , 1870-1874. (Pubitemid 16176843)
32. Aubart, K. and Zalacain, M. (2006) Peptide Deformylase Inhibitors Prog. Med. Chem. 44 109-143.
33. Jain, R., Chen, D., White, R.J., Patel, D.V. and Yuan, Z. (2005) Bacterial Peptide Deformylase Inhibitors: A New Class of Antibacterial Agents Curr. Med. Chem. 12 1607-1621. (Pubitemid 40895004)
34. Smith, K., Petit, C., Aubart, K., Smyth, M., McManus, E., Jones, J., Fosberry, A., Lewis, C., Lonetto, M. and Christensen, S. (2003) Structural variation and inhibitor binding in polypeptide deformylase from four different bacterial species. Prot. Sci. 12, 349-360. (Pubitemid 36120347)
35. East, S., Beckett, R., Brookings, D., Clements, J., Doel, S., Keavey, K., Pain, G., Smith, H., Thomas, W., Thompson, A., Todd, R. and Whittaker, M. (2004) Peptide deformylase inhibitors with activity against respiratory tract pathogens. Bioorg. Med. Chem. Lett. 14, 59-62. (Pubitemid 38010194)
36. Azoulay-Dupuis, E., Mohler, J. and Bedos, J. (2004) Efficacy of BB-83698, a Novel Peptide Deformylase Inhibitor, in a Mouse Model of Pneumococcal Pneumonia. Antimicrob. Agents Chemother. 48, 80-85. (Pubitemid 38040180)
37. Clements, J., Beckett, R., Brown, A., Catlin, G., Lobell, M., Palan, S., Thomas, W., Whittaker, M., Wood, St., Salama, S., Baker, P., Rodgers, H., Barynin, V., Rice, D. and Hunter, M. (2001) Antibiotic Activity and Characterization of BB-3497, a Novel Peptide Deformylase Inhibitor. Antimicrob. Agents Chemother. 45, 563-570. (Pubitemid 32105294)
38. Davies, S., Ayscough, A., Beckett, R., Clements, J., Doel, S., Pratt, L., Spavold, Z., Thomas, S. and Whittaker, M. (2003) Structure-Activity Relationships of the Peptide Deformylase Inhibitor BB-3497: Modification of the P2 c and P3 ¢ Side Chains. Bioorg. Med. Chem. Lett. 13 , 2715-2718. (Pubitemid 36851556)
39. Ramanathan-Girish, S., McColm, J., Clements, J., Taupin, P., Barrowcliffe, S., Hevizi, J., Safrin, S., Moore, C., Patou, G., Moser, H., Gadd, A., Hoch, Ute, Jiang, V., Lofland, D. and Johnson, K. (2004) Pharmacokinetics in Animals and Humans of a First-in-Class Peptide Deformylase Inhibitor. Antimicrob. Agents Chemother. 48, 4835-4842. (Pubitemid 39577691)
40. Chen, D., Hackbarth, C., Ni, Z., Wu, C., Wang, W., Jain, R., He, Y., Bracken, K., Weidmann, B., Patel, D., Trias, J., White, R. and Yuan, Z. (2004) Peptide Deformylase Inhibitors as Antibacterial agents: Identification of BRC3375, a Proline-3-Alkylsuccinyl Hydroxamate Derivative, by Using an Integrated Combinatorial and Medicinal Chemistry Approach. Antimicrob. Agents Chemother. 48, 250-261. (Pubitemid 38040205)
41. Hackbarth, C., Chen, D., Lewis, J., Clark, K., Mangold, J., Cramer, J., Margolis, P., Wang, W., Koehn, J., Wu, C., Lopez, S., Withers, G., Gu, H., Dunn, E., Kulathila, R., Pan, S., Porter, W., Jacobs, J., Trias, J., Patel, D., Weidmann, B., White, R. and Yuan, Z. (2002) N -Alkyl Urea Hydroxamic Acids as a New Class of Peptide Deformylase Inhibitors with Antibacterial Activity. Antimicrob. Agents Chemother. 46, 2752-2764.
42. Aubart, K., Benowitz, A., Campobasso, N., Dreabit, J., Fang, Y., Karpinski, J., Kelly, S., Liao, X., Lee, J., Mercer, D., Lewandowski, T., VanAller, G., Zonis, R., Christensen, S. and Zalacain, M. (2010) "Hydrazinopyrimidines as a New Class of Peptide Deformylase Inhibitors" 50 th ICAAC Meeting: Boston, MA (poster F1-2110).
43. Qin, D., Fang, Y., Benowitz, A., Liao, X., Karpinski, J., Dreabit, J., Knox, A., Kelly, S., Axten, J., Mercer, D., Kulkarni, S., Campobasso, N., Zonis, R., VanAller, G., Christensen, S., Zalacain, M. and Aubart, K. (2010) "Peptide Deformylase Inhibitors: Discovery of a Clinical Candidate from a Novel Chemical Class" 50 th ICAAC Meeting: Boston, MA (poster F1-2111).
44. Margolis, P., Hackbarth, C., Young, D., Wang, W., Chen, D., Yuan, Z., White, R. and Trias, J. (2000) Peptide Deformylase in Staphylococcus aureus : Resistance to Inhibition Is Mediated by Mutations in the Formyltransferase Gene. Antimicrob. Agents Chemother. 44, 1825-1831. (Pubitemid 30422931)
45. Lu, H. and Tonge, P. (2008) Inhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway. Accounts Chem. Res. 41 , 11-20.
46. Payne, D. J., Warren, P. V., Holmes, D. J., Ji, Y. and Lonsdale, J. T. (2001) Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery. Drug Disc. Today 6 , 537-544. (Pubitemid 32452153)
47. Seefeld, M. A., Miller, W. H., Newlander, K. A., Burgess, W. J., Payne, D. J., Rittenhouse, S. F., Moore, T. D., DeWolf, W. E., Keller, P. M., Qiu, X., Janson, C. A., Vaidya, K., Fosberry, A. P., Smyth, M. G., Jaworski, D. D., Slater-Radosti, C. and Huffman, W. F. (2001) Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3, 4-b]indoles as potential antibacterial agents. Bioorg. Med. Chem. Lett. 11 , 2241-2244. (Pubitemid 32781674)
48. Heerding, D. A., Chan, G., DeWolf, W. E., Fosberry, A. P., Janson, C. A., Jaworski, D. D., McManus, E., Miller, W. H., Moore, T. D., Payne, D. J., Qiu, X., Rittenhouse, S. F., Slater- Radosti, C., Smith, W., Takata, D. T., Vaidya, K. S., Yuan, C. C. K. and Huffman, W. F. (2001) 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI). Bioorg. Med. Chem. Lett. 11 , 2061-2065. (Pubitemid 32763001)
49. Miller, W. H., Seefeld, M. A., Newlander, K. A., Uzinskas, I. N., Burgess, W. J., Heerding, D. A., Yuan, C. C. K., Head, M. S., Payne, D. J., Rittenhouse, S. F., Moore, T. D., Pearson, S. C., Berry, V., DeWolf, W. E., Jr., Keller, P. M., Polizzi, B. J., Qiu, X., Janson, C. A. and Huffman, W. F. (2002) Discovery of Aminopyridine-Based Inhibitors of Bacterial Enoyl-ACP Reductase (FabI). J. Med. Chem. 45 , 3246-3256. (Pubitemid 34774275)
50. Seefeld, M. A., Miller, W. H., Newlander, K. A., Burgess, W. J., DeWolf, W. E. Jr., Elkins, P. A., Head, M. S., Jakas, D. R., Janson, C. A., Keller, P. M., Manley, P. J., Moore, T. D., Payne, D. J., Pearson, S., Polizzi, B. J., Qiu, X., Rittenhouse, S. F., Uzinskas, I. N., Wallis, N. G. and Huffman, W. F. (2003) Indole Naphthyridinones as Inhibitors of Bacterial Enoyl-ACP Reductases FabI and FabK. J. Med. Chem . 46 , 1627-1635. (Pubitemid 36444216)
51. Payne, D. J., Miller, W. H., Berry, V., Brosky, J., Burgess, W. J., Chen, E., DeWolf, W. E., Jr., Fosberry, A. P., Greenwood, R., Head, M. S., Heerding, D. A., Janson, C. A., Jaworski, D. D., Keller, P. M., Manley, P. J. Moore, T. D., Newlander, K. A., Pearson, S., Polizzi, B. J., Qiu, X., Rittenhouse, S. F., Slater-Radosti, C., Salyers, K. L., Seefeld, M. A., Smyth, M. G., Takata, D. T., Uzinskas, I. N., Vaidya, K., Wallis, N. G., Winram, S. B., Yuan, C. C. K. and Huffman, W. F. (2002) Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. 46 , 3118-3124.
52. Karlowsky, J. A., Laing, N. M., Baudry, T., Kaplan, N., Vaughan, D., Hoban, D. J. and Zhanel, G. G. (2007) In vitro activity of API - 1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. 51 , 1580-1581. (Pubitemid 46586859)
53. Karlowsky J. A., Kaplan N., Hafkin B., Hoban D. J. and Zhanel G. G. (2009) AFN-1252, a FabI inhibitor, demonstrates a Staphylococcusspecific spectrum of activity. Antimicrob. Agents Chemother. 53 , 3544-3548.
54. Yum, J. H., Kim, C. K., Yong, D., Lee, K., Chong, Y., Kim, C. M., Kim, J. M. Ro, S. and Cho, J. M. (2007) In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob. Agents Chemother. 51 , 2591-2593. (Pubitemid 47047342)
55. Bogdanovich, T., Clark, C., Kosowska-Shick, K., Dewasse, B., McGhee, P. and Appelbaum, P. C. (2007) Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. Antimicrob. Agents Chemother. 51 , 4191-4195. (Pubitemid 350057828)
56. Kitagawa, H., Ozawa, T., Takahata, S., Iida, M., Saito, J. and Yamada, M. (2007) Phenylimidazole Derivatives of 4-Pyridone as Dual Inhibitors of Bacterial Enoyl-Acyl Carrier Protein Reductases FabI and FabK. J. Med. Chem . 50 , 4710-4720. (Pubitemid 47463244)